MRI contrast-enhancing agents

Phase 3Small molecule

MRI contrast-enhancing agents is one of 52 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

TumorNot yet recruiting

Secondary Progressive Multiple SclerosisRecruiting

Multiple SclerosisPhase 3

Active, not recruiting

TumorPhase 1

Not yet recruiting

Secondary Progressive Multiple SclerosisPhase 3

Recruiting

Competition

Competitive Landscape

138 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Vumerity

Biogen

Phase 3

5 4

Clemastine Fumarate

Novartis

Phase 3

2 5

Activated Charcoal

Sanofi

Phase 3

1 6

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 7

Frexalimab

Sanofi

Phase 3

2 8

MRI contrast-enhancing agents

Sanofi

Phase 3

3 9

PBR06

UUniversity Hospital, Bordeaux

Phase 3

4 10

Flomax

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Multiple Sclerosis

NCT06141473

Q3 2027

Phase 2Active, not recruiting

Multiple Sclerosis

NCT04879628

Q1 2028

Phase 3Recruiting

Secondary Progressive Multiple Sclerosis

NCT06141486

Q3 2028

Phase 1Not yet recruiting

Tumor

NCT07066436

Clinical

Trials by Indication[1]

Multiple Sclerosis3 trials

A Randomized, Phase 3, Open-label Study to Investigate Pharmacokinetics, Safety, and Efficacy of Subcutaneous Compared to Intravenous Frexalimab in Adult Participants With Multiple Sclerosis

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07325292·160 enrolled

A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT04879628·129 enrolled

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06141473·1,655 enrolled

Tumor1 trial

ImmunoMRI for Assessment of Tumor-associated Macrophages

Not yet recruiting·MMedical University of Vienna·Phase 1·NCT07066436·60 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06141486·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MRI contrast-enhancing agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRI contrast-enhancing agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRI contrast-enhancing agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

MRI contrast-enhancing agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Multiple Sclerosis3 trials

Tumor1 trial

Secondary Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News